Aimovig

Aimovig launch bolsters hopes for blockbuster sales
Aimovig launch bolsters hopes for blockbuster sales
Biopharma Dive
Aimovig
Amgen
Novartis
migraines
Flag link:
Amgen's new migraine drug hits insurance hurdles
Amgen's new migraine drug hits insurance hurdles
Reuters
Amgen
migraines
Aimovig
insurers
Flag link:
Amgen, Novartis 'overwhelmed' by early interest in migraine drug Aimovig: expert
Amgen, Novartis 'overwhelmed' by early interest in migraine drug Aimovig: expert
Fierce Pharma
migraines
Amgen
Novartis
Aimovig
Flag link:
Migraine Breakthrough: Not So Fast
Migraine Breakthrough: Not So Fast
Forbes
Amgen
Novartis
Aimovig
migraines
adults
monoclonal antibodies
Flag link:
Thanks to lower-than-expected price, ICER backs Amgen's Aimovig—but only after other meds fail
Thanks to lower-than-expected price, ICER backs Amgen's Aimovig—but only after other meds fail
Fierce Pharma
Amgen
ICER
Aimovig
migraines
Flag link:
Will Amgen’s migraine win and 5th thumbs-up for Prolia drive enough growth? Nope, says analyst
Will Amgen’s migraine win and 5th thumbs-up for Prolia drive enough growth? Nope, says analyst
Fierce Pharma
Amgen
FDA
Aimovig
migraines
Prolia
Flag link:
Migraine prevention drug could be worth $1 to $2 billion over next five years: Wall Street analyst
Migraine prevention drug could be worth $1 to $2 billion over next five years: Wall Street analyst
CNBC
migraines
Amgen
Novartis
Aimovig
Flag link:
Amgen’s new migraine drug will cost 30 percent less than Wall Street expected
Amgen’s new migraine drug will cost 30 percent less than Wall Street expected
Stat
Amgen
Novartis
migraines
Aimovig
drug pricing
Flag link:
Amgen's Aimovig won its first-in-class migraine nod. Will payers step up to the $6,900 price?
Amgen's Aimovig won its first-in-class migraine nod. Will payers step up to the $6,900 price?
Fierce Pharma
Amgen
Novartis
Aimovig
FDA
migraines
Flag link:
12 blockbusters: The surging list of $1B-plus drugs rolling out on the market this year might surprise you
12 blockbusters: The surging list of $1B-plus drugs rolling out on the market this year might surprise you
Endpoints
drug launches
Hemlibra
Roche
Biktarvy
Gilead Sciences
Ozempic
Novo Nordisk
Erleada
JNJ
Shingrix
GSK
Patisiran
Alnylam
Sanofi
Epidiolex
GW Pharma
Aimovig
Amgen
Novartis
lanadelumab
Shire
Elagolix
AbbVie
Steglatro
Pfizer
Merck
Sublocade
Indivior
Flag link:
Novartis Expects FDA and EMA Approvals for Aimovig in 2018
Novartis Expects FDA and EMA Approvals for Aimovig in 2018
Yahoo/Market Realist
Novartis
FDA
EMA
drug approvals
Aimovig
migraines
Flag link:
Amgen pulls ahead in sprint towards CGRP approval with promising PhIII migraine data
Amgen pulls ahead in sprint towards CGRP approval with promising PhIII migraine data
Endpoints
Amgen
CGRP blockers
migraines
Aimovig
erenumab
Flag link:
Amgen and Novartis ID the finish line in a wicked scramble for first CGRP migraine drug OK
Amgen and Novartis ID the finish line in a wicked scramble for first CGRP migraine drug OK
Endpoints
Amgen
Novartis
migraines
CGRPs
Aimovig
Flag link:

Pages